Bisteric inhibitors combine allosteric binding with an ATP-competitive inhibitory mechanism (13) and more durably suppress mTORC1 outputs, including phosphorylation of 4EBP1, than do allosteric inhibitors in models of glioma (9). The gene discussed is EIF4EBP1; the disease is central nervous system cancer.